Li Xue, Geng Xiaokun, Fan Junfen, Yan Feng, Wang Rongliang, Yang Zhenhong, Li Yuqian, Wang Jing, Luo Yumin, Zhao Haiping
Institute of Cerebrovascular Disease Research, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Beijing, 100053, China.
Beijing Geriatric Medical Research Center, Beijing, 100053, China.
Mol Neurobiol. 2025 May;62(5):6544-6561. doi: 10.1007/s12035-025-04699-7. Epub 2025 Jan 17.
High concentrations of neutrophil degranulation products in the plasma and thrombi are poor prognostic indicators in patients with acute ischemic stroke (AIS). This study aimed to identify candidate effectors capable of mediating neutrophil degranulation post-AIS, and to reveal their underlying epigenetic mechanisms. Microarrays and ChIP-seq were applied to analyze the neutrophils of patients with AIS. Cerebral ischemia was induced in C57/BL6 mice by middle cerebral artery occlusion (MCAO). Lipopolysaccharide was used to induce inflammation in HL-60 Cells. Protein and mRNA levels were assessed using flow cytometry, ELISA, western blotting, and RT-PCR. Degranulation was identified as a significant pathway in the neutrophils of patients with AIS, while Rho GTPase and the SNARE complex also showed importance. HDAC2 differentially binds to genes involved in neutrophil degranulation in patients with AIS. SYT9, SH3BP1, and STXBP1 were identified in two sequencing experiments, for which HDAC2 bound to their promoter, intron, and upstream regions, respectively. Consistently, candidate degranulation effectors and products showed substantially increased expression and co-localization in the neutrophils of thrombi obtained from patients with middle cerebral artery stenosis with poor prognosis, a mouse model of MCAO, and an HL-60 cell-based model of inflammation. Knockdown of SYT9, SH3BP1, and STXBP1 impaired primary granule release in vitro, whereas HDAC2 activity was decreased following LPS induction and ischemic stroke in mice. Furthermore, HDAC2 inhibition upregulated SYT9, SH3BP1, and STXBP1. Our findings suggest that these three molecules may be indispensable in the process of neutrophil degranulation following AIS, and are targeted by HDAC2, paving the way for the development of new drugs.
血浆和血栓中高浓度的中性粒细胞脱颗粒产物是急性缺血性卒中(AIS)患者预后不良的指标。本研究旨在确定能够介导AIS后中性粒细胞脱颗粒的候选效应分子,并揭示其潜在的表观遗传机制。应用微阵列和染色质免疫沉淀测序(ChIP-seq)分析AIS患者的中性粒细胞。通过大脑中动脉闭塞(MCAO)在C57/BL6小鼠中诱导脑缺血。使用脂多糖诱导HL-60细胞发生炎症。采用流式细胞术、酶联免疫吸附测定(ELISA)、蛋白质免疫印迹法和逆转录-聚合酶链反应(RT-PCR)评估蛋白质和mRNA水平。脱颗粒被确定为AIS患者中性粒细胞中的一条重要途径,而Rho鸟苷三磷酸酶(GTPase)和可溶性N-乙基马来酰胺敏感因子附着蛋白受体(SNARE)复合体也显示出重要性。组蛋白去乙酰化酶2(HDAC2)与AIS患者中性粒细胞脱颗粒相关基因存在差异结合。在两项测序实验中鉴定出突触结合蛋白9(SYT9)、SH3结构域结合蛋白1(SH3BP1)和 syntaxin结合蛋白1(STXBP1),HDAC2分别与它们的启动子、内含子和上游区域结合。一致的是,在预后不良的大脑中动脉狭窄患者的血栓、MCAO小鼠模型以及基于HL-60细胞的炎症模型中,候选脱颗粒效应分子和产物在中性粒细胞中的表达和共定位显著增加。敲低SYT9、SH3BP1和STXBP1会损害体外初级颗粒释放,而在小鼠中,脂多糖诱导和缺血性卒中后HDAC2活性降低。此外,HDAC2抑制上调了SYT9、SH3BP1和STXBP1。我们的研究结果表明,这三种分子可能在AIS后中性粒细胞脱颗粒过程中不可或缺,并且是HDAC2的作用靶点,为新药开发铺平了道路。